MCM
ECYT

Matarin Capital Management’s Endocyte, Inc. Common Stock ECYT Stock Holding History

Matarin Capital Management’s Portfolio ECYT Stock Details ECYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-39,307
Closed -$59K – 312
2017
Q2 		$59K Hold
39,307
– – 0.01% 275
2017
Q1 		$101K Buy
+39,307
New +$90.9K 0.01% 281

Other funds holding ECYT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Matarin Capital Management's ECYT Position: Q3 2017 in Review

Matarin Capital Management sold out of Endocyte, Inc. Common Stock (ECYT) in Q3 2017, closing a stake of 39,307 shares — an estimated $59K sold.

Matarin Capital Management first reported a position in ECYT in Q1 2017 and held it in 2 quarters. The position peaked at $101K in Q1 2017. 63 funds tracked by Wall St. Rank hold ECYT as of Q3 2017.

  • Matarin Capital Management reported no remaining Endocyte, Inc. Common Stock position as of Q3 2017 after selling out during the quarter.
  • Matarin Capital Management sold 39,307 Endocyte, Inc. Common Stock shares in Q3 2017, an estimated $59K.
  • Matarin Capital Management first reported a position in Endocyte, Inc. Common Stock in Q1 2017 and held it in 2 quarters.
  • Matarin Capital Management's Endocyte, Inc. Common Stock position peaked at $101K in Q1 2017.
  • 63 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q3 2017.

Based on Matarin Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.